Also, whats the potential impact on Narayana as they mostly do specilised treatments/surgeries? Current fall in NH share on the back of this development offers good margin of safety, given the company is consistently growing at 20% EPS and valuation (EV/EBITDA) appears reasonable vs peers.

Any thoughts?

Haven’t been able to maintain my PF excel (more on this later) lately so providing a summary below:

After PPFAS, my top 5 holdings are: Godrej agrovet, Triveni, ami, sansera and exide.
a) Added some AMI and Sansera over the last few weeks.
b) In terms of exits, BCL Industries (~40%), M.K Ventures (approx 20% up), Cosmo First (this was 15 or 20 % down as far as I can remember).
c) Exited Helios and removed it from my watchlist. Deployed funds in Kenneth’s fund during the FPO (currently ~3.5% PF).

What I am looking at:

• Chemicals.
  a) At 1600/1700 market cap, Astec seemed very interesting so I took an entry and added. This conflicts with Godrej Agrovet so I will need to review things here once I get brainstorming time.
  b) Reviewing other opportunities here.

• Consumers and others:
  a) VIP Ind, Tasty Bite, V Guard, Indigo, and Creative Newtech are on my watchlist.
  b) Have taken a very small position in Creative but I am not sure if I will be able to take a large position here.
  c) Something similar happened in VIP industries where I added and exited within the same week. But it seems very interesting.

These are some of the major changes I can think of. There were some other transactions too but I will need some time to maintain everything in my excel again and then update here.

As of now, I am burdened with a few things in my personal life which should last for a year or two. Luckily, I saw it coming earlier and was able to make most bets accordingly. I think I’ll be able to update properly after June or else September/October this year but too soon to confirm so let’s see.

Disclaimer: I am not a SEBI registered advisor or analyst. This is my personal view and not a recommendation. I am often wrong and do change my views without being able to inform anyone.

@rjs391

I usually look at weekly charts for positional medium to long term buys. If there is any visible bullish formation, I try to go one period lower, i.e daily chart and look at it. With these kind of workings, I have a list of around 30-40 stocks which remain in my watchlist. (this is based on charts and fundamentals. )

For investment purpose, I have around 8-10 stocks in my portfolio and remaining 25-30 remain in watchlist. If something from the watchlist appears better and if the picture and investment merits are much more clearer, then I often replace something from my portfolio or add it as an additional stock.

I do not have any formula based approach to portfolio allocation. It depends upon the conviction levels and market mood.

About booking partial profits and taking money out, I usually do not do it except in some cases to pay taxes. Usually I keep the full portfolio running and try to enjoy the benefits of compounding. It has worked well till now over all these years.

As article points out, Kotak estimates very low probability of applying this type of law.
Nomura says if middle ground is taken, it can be implemented on non complex procedures. However, this reminds of regulatory risk and it may overhang on all hospital stocks.
D: Invested

I have exited the most of the allocation as uptick in revenues and profit is seems to be impossible in the FY25 itself.

Something wrong with capsules business also, earlier they were telling sluggish demand due to pharma companies are with excess inventory. Now all pharma company numbers are good still they are not able to see jump in numbers, this could be due to price erosion and excess supply from competitors also.

I will revisit once API segment make some +ve EBITDA